Skip to main content
. 2021 Feb 1;78(4):1–7. doi: 10.1001/jamaneurol.2020.5157

Figure 1. Cumulative Incidence of Parkinson Disease (PD) in the Danish and Truven Cohorts.

Figure 1.

A, Kaplan-Meier plot of Danish nationwide health registries, including the Danish National Prescription Registry, the Danish National Patient Registry, and the Danish Civil Registration System. B, Kaplan-Meier plot of Truven Health Analytics MarketScan database. The lines denote the Kaplan-Meier estimated cumulative incidence of PD by cohort while the shaded regions denote the 95% CIs. The Truven cohort terminates at 15 years, as that is the longest possible follow-up in that database, while the Danish cohort has 5 additional years of follow-up possible. In both samples, use of terazosin (TZ), doxazosin (DZ), or alfuzosin (AZ) was associated with lower cumulative incidence of PD compared with use of tamsulosin.